Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response-The TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial

Platelets

Volumn 25, Issue 7, 2014, Pages 506-512

  Dridi, Nadia Paarup ^a   Johansson, Pär Ingemar ^b   Clemmensen, Peter ^a   Stissing, Trine ^b   Radu, Maria Dumitrela ^a   Qayyum, Abbas ^a   Pedersen, Frants ^a   Helqvist, Steffen ^a   Saunamäki, Kari ^a   Kelbæk, Henning ^a   Jorgensen, Erik ^a   Engstrom, Thomas ^a   Holmvang, Lene ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antiplatelet therapy; Clopidogrel; High on treatment platelet reactivity; Multiplate; Prasugrel

Indexed keywords

CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; PROCEDURES; PROGNOSIS; THROMBOCYTE; TREATMENT OUTCOME;

AGED; BLOOD PLATELETS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84912027505     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.845874     Document Type: Article

References (42)

1. Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010;103:151-159
2. Cuisset T, Frere C, Quilici J, et al. High post-Treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549
3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057
4. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009;373: 723-731
5. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet 2010;376:1233-1243
6. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-Treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-933
7. Neubauer H, Kaiser AF, Endres HG, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 2011;9:3
8. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011;305:1097-1105
9. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367: 2100-2109
10. Price MJ. Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: Clarifying the time and place for intensive inhibition. JAMA 2012;308: 1806-1808
11. Siller-Matula JM, Gouya G, Wolzt M, et al. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009;102:397-403
12. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-856
13. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111: 1153-1159
14. Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008;6:54-61
15. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750
16. Wurtz M, Hvas AM, Kristensen SD, et al. Platelet aggregation is dependent on platelet count in patients with coronary artery disease. Thromb Res 2012;129:56-61
17. Kaiser AF, Neubauer H, Franken CC, et al. Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions. Platelets 2012;23:359-367
18. Johnston LR, Larsen PD, La Flamme AC, et al. Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate(R) analyser. Platelets 2013;24:303-307
19. Cutlip DE, Nakazawa G, Krucoff MW, et al. Autopsy validation study of the academic research consortium stent thrombosis definition. JACC Cardiovasc Interv 2011;4:554-559
20. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-2747
21. Angiolillo DJ, Saucedo JF, DeRaad R, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010;56:1017-1023
22. Pena A, Collet JP, Hulot JS, et al. Can we override clopidogrel resistance? Circulation 2009;119:2854-2857
23. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-And maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-2932
24. Montalescot G, Sideris G, Cohen R, et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010;103: 213-223
25. Erlinge D, Ten BJ, Foley D, et al. Reduction in platelet reactivity with prasugrel 5mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: Results from the FEATHER trial. J Am Coll Cardiol 2012;60:2032-2040
26. Erlinge D, Gurbel PA, James S, et al. Prasugrel 5mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10 mg in nonelderly patients: The GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol 2013;62:577-583
27. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high onclopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study. J Am Coll Cardiol 2012; 60:193-199
28. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-Treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173
29. Franken CC, Kaiser AF, Kruger JC, et al. Cytochrome P450 2B6 and 2C9 genotype polymorphism-A possible cause of prasugrel low responsiveness. Thromb Haemost 2013;110:131-140
30. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367: 2100-2109
31. Siller-Matula JM, Francesconi M, Dechant C, et al. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2012;167:2018-2023
32. Sibbing D, von BO, Schomig A, et al. Platelet function in clopidogrel-Treated patients with acute coronary syndrome. Blood Coagul Fibrinolysis 2007;18:335-339
33. Bonello L, Pansieri M, Mancini J, et al. High on-Treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-473
34. Mega JL, Hochholzer W, Frelinger III AL, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306: 2221-2228
35. Gurbel PA, Erlinge D, Ohman EM, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with acs treated without revascularization: The TRILOGY ACS platelet function substudy. JAMA 2012;308:1785-1794
36. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012;59:2159-2164
37. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011;305:1097-1105
38. Stellbaum C, Ayral Y, Morguet A, et al. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry. Cardiovasc Revasc Med 2012;13:159-166
39. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013;381:1107-1115
40. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-2944
41. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32: 2999-3054
42. Grove EL, Hvas AM, Mortensen SB, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011;9:185-191